DNA damage-induced apoptosis suppressor protein (DDIAS)

DNA damage-induced apoptosis suppressor protein (DDIAS) is an oncogenic protein highly expressed in multiple human cancers, including lung, hepatic, colorectal, breast cancer, and gliomas[1][2][3]. It acts as an anti-apoptotic factor by protecting tumor cells from DNA damage-induced cell death, promoting cell proliferation, driving cell cycle progression, enhancing DNA synthesis (interacting with DNA polymerase α), and supporting cell migration and metastasis[2][3]. DDIAS suppresses apoptosis by interfering with tumor suppressor pathways and signaling proteins such as STAT3 and LEF1, and by facilitating DNA repair, thereby contributing to tumorigenesis, drug resistance (e.g., to cisplatin and TRAIL), and poor patient prognosis[1][2][3][4]. DDIAS is regulated post-translationally via proteasomal degradation mediated by chaperones (HSP70) and the E3 ubiquitin ligase CHIP, while upstream transcriptional control involves stress signaling pathways (NFAT, EGF/ERK5/MEF2B)[1][3]. Its cancer-selective role and absence of essential function in normal cells point to its therapeutic promise as an anti-cancer target, with research ongoing to develop direct DDIAS inhibitors or degraders[1][3].

Other names

noxinC11orf82NOXINFLJ38838FLJ25416Nitric oxide-inducible gene proteinnitric oxide-inducibleDNA damage induced apoptosis suppressorDNA damage-induced apoptosis suppressor protein

Potential drugs targeting DDIAS would function by inhibiting its anti-apoptotic activity, making cancer cells more sensitive to DNA damage, and overcoming drug resistance[1][3]. Supporting mechanisms include depletion/degradation of DDIAS (e.g., via U-box E3 ligase CHIP/HSP70 axis) to restore DNA damage-induced apoptosis[1].